EDITORIAL
Familial Pulmonary Fibrosis
 
More details
Hide details
1
2nd Pneumonology Medicine Department, “Attikon” University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
 
2
7th Department of Pneumonology and Asthma Center, “Sotiria” Chest Diseases Hospital, Greece
 
3
APHP Service de Génétique, Hôpital Bichat, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
 
4
APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE Centre de Competence des Maladies Pulmonaires Rares, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
 
5
1st Department of Pneumonology, “Sotiria” Chest Diseases Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
 
 
Corresponding author
Effrosyni D. Manali   

2nd Pneumonology Medicine Department, “Attikon” University Hospital, 1 Rimini Street, 12462, Haidari, Greece
 
 
Pneumon 2016;29(2):114-119
 
ACKNOWLEDGEMENTS
The authors would like to greatly thank the following colleagues for their precious collaboration concerning familial pulmonary fibrosis patients in Greece: V. Tzilas, E. Bouros, A. Xifteri, M. Gaggadi, A. Charitou, Aik. Markopoulou, E. Fouka, H. Papanikolaou, Chr. Bazaka, I. Korbila, G. Papadaki, P. Lyberopoulos, S. Laparidou, Z. Sardelis, E. Markozannes, M. Kasiola, T. Tsiligiannis, P. Steiropoulos, P. Bakakos, S. Loukides.
 
REFERENCES (64)
1.
Borie R, Kannengiesser C, Nathan N, et al. Familial pulmonary fibrosis. Rev Mal Respir 2015; 32:413-34.
 
2.
Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med 2014; 2:416-28.
 
3.
Okamoto T, Miyazaki Y, Tomita M, et al. A familial history of pulmonary fibrosis in patients with chronic hypersensitivity pneumonitis. Respiration 2013; 85:384-90.
 
4.
Nogee LM, Dunbar AE III, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344:573-9.
 
5.
Watanabe K. Pleuroparenchymal Fibroelastosis: its clinical characteristics. Curr Respir Med Rev 2013; 9:229-37.
 
6.
Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172:1146-52.
 
7.
Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57:338-42.
 
8.
Mathai SK, Schwartz DA, Wang LA. Genetic susceptibility and pulmonary fibrosis. Curr Opin Pulm Med 2014; 20:429-35.
 
9.
Kropski JA, Blackwell TS, Loyd JE. The genetic basis of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45:1717-27.
 
10.
Antonarakis SE, Chakravarti A, Cohen JC, et al. Mendelian disorders and multifactorial traits: the bog divide or one for all? Nat Rev Genet 2010; 11:380-4.
 
11.
Chu SG, El-Chemaly S, Rosas IO. Genetics and Idiopathic Interstitial Pneumonias. Semin Respir Crit Care Med 2016; 37:321-30.
 
12.
Kropski JA, Lawson WE, Young LR, et al. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Mod Mech 2013; 6:9-17.
 
13.
Thomas AQ, Lane K, Philipps J III, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165:1322-8.
 
14.
Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84:52-9.
 
15.
Van Moorsel CHM, van Oosterhout FM, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010; 182:1419-25.
 
16.
Nathan N, Giraud V, Picard C, et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet 2016; 25:1457-67.
 
17.
Bullard JE, Wert SE, Whitsett JA, et al. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 2005; 172:1026-31.
 
18.
Bullard JE, Nogee LM. Heterozygocity for ABCA3 mutations modifies the severity of lung disease associated with a surfactant protein C gene (SFTPC) mutation. Pediatr Res 2007; 62:176-9.
 
19.
Garmany TH, Moxley MA, White FV, et al. Surfactant composition and function in patients with ABCA3 mutations. Pediatr Res 2006; 59:801-5.
 
20.
Mulugeta S, Nureki SI, Beers MF. Lost after translation: insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2015; 309:L507-25.
 
21.
Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356:1317-26.
 
22.
Tsakiri KD, Cronkhite JT, Kuan PJ et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl AcadSci USA 2007; 104:7552-7.
 
23.
Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361:2353-65.
 
24.
Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenital. Nature 2001; 413:432-5.
 
25.
Diaz de Leon A, Cronkhite JT, Katzenstein ALA, et al. Telomere lengths, pulmonary fibrosis and telomerase mutations. PLoS one 2010; 5:e10680.
 
26.
Alder JK, Parry EM, Yegnasubramanian S, et al. Telomere phenotypes in females with heterogyzous mutations in the dyskeratosis congenital 1 gene. Hum Mutat 2013; 34:1481-5.
 
27.
Fukuhara A, Tanino Y, Ishii T et al. Pulmonary fibrosis in dyskeratosis congenital with TINF2 gene mutation. Eur Respir J 2013; 42:1757-9.
 
28.
Stuart BD, Choi J, Zaidi S, et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet 2015; 47:512-7.
 
29.
Kannengiesser C, Borie R, Ménard C, et al. Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. Eur Respir J 2015; 46:474-85.
 
30.
Cogan JD, Kropski JA, Zhao M, et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 2015; 191:646-55.
 
31.
Armanios MY, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012; 13:693-704.
 
32.
Armanios MY. Telomeres and age-related disease: how telomere biology informs clinical paradigms. J Clin Invest 2013; 123:996-1002.
 
33.
Batista LF, Pech MF, Zhong FL, et al. Telomere shortening and loss of self-renewal in dyskeratosis congenital induced pluripotent stem cells. Nature 2011; 474:399-402.
 
34.
Hoffmeyer K, Raggioli A, Rudloff S, et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012; 336:1549-54.
 
35.
Cronkhite JK, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178:729-37.
 
36.
Alder JK, Barkauskas CE, Limjunyawong N, et al. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci USA 2015; 112:5099-104.
 
37.
Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364:1503-12.
 
38.
Peljto AL, Selman M, Kim DS, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican Cohort but is rare among Asian ancestries. Chest 2015; 147:460-4.
 
39.
Borie R, Crestani B, Dieudé P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PloS one 2013; 8:e70621.
 
40.
Yang IV, Fingerlin TE, Evans CM, et al. MUC5B and idiopathic pulmonary fibrosis. Ann Am Thorac Soc 2015; 12:S193-9.
 
41.
Roy MG, Livragni-Butrico A, Fletcher AA, et al. MUC5B is required for airway defense. Nature 2014; 505:412-6.
 
42.
Lee HL, Ruy J, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis. Clinical features and outcome. Chest 2005; 127:2034-41.
 
43.
Garcia-Sancho C, Buendia-Roldán I, Fernández-Plata MR, et al. Familial Pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Res Med 2011; 105:1902-7.
 
44.
Scholand MB, Coon H, Wollf R, et al. Use of genealogical database demonstrates heritability of pulmonary fibrosis. Lung 2013; 191:475-81.
 
45.
Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Res Res 2012;13:64.
 
46.
Rosas IO, Pen P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698-705.
 
47.
Lee HY, Seo JB, Steele M, et al. High resolution CT scan findings in familial interstitial pneumonia do not conform to those of idiopathic interstitial pneumonia. Chest 2012; 142:1577-83.
 
48.
Calado RT, Brucho J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology 2011; 53:1600-7.
 
49.
Calado RT, Regal JA, Kleiner DE, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. Plos ONE 2009; 4:E7926.
 
50.
Towsley DM, Dimitriu B, Young NS. Bone marrow failure and telomeropathies. Blood 2014; 124:2775-83.
 
51.
Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase in aplastic anemia. N Engl J Med 2005; 352:1413-24.
 
52.
Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44:178-87.
 
53.
Borie R, Kannengiesser C, Hirchi S, et al. Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transpl 2015; 34:538-46.
 
54.
George G, Rosas IO, Cui Y, et al. Short telomeres, telomeropathy and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest 2015; 147:1549-57.
 
55.
Peljto A, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309:2232-9.
 
56.
Van der Vis JJ, Snetselaar R, Kazemier KM, et al. Effect of MUC5B promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. Respirology 2016; 21:712-7.
 
57.
Wambach JA, Casey AM, Fishman MP, et al. Genotype-phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med 2014; 189:1538-43.
 
58.
Epaud R, Delestrain C, Louha M, et al. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J 2014; 43:635-8.
 
59.
Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 2011; 66:918-9.
 
60.
Kropski JA, Pritchett JM, Zoz DF, et al. Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 2015; 191:417-26.
 
61.
Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases. N Engl J Med 2016; 374:1922-31.
 
62.
Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014; 189:770-8.
 
63.
Mathai SK, Yang IV, Schwartz MI, et al. Incorporating genetics into the identification and treatment of Idiopathic pulmonary fibrosis. BMC Med 2015; 24;13:191.
 
64.
Marian AJ. Challenges in medical applications of whole exome/ genome sequencing discoveries. Trends Cardiovasc Med 2012; 22:219-23.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top